105GTN201: TRC105 in Refractory Gestational Trophoblastic Neoplasia

• Research type

  Research Study

• Full title

  A PHASE 2A STUDY OF TRC105 (WITH OPTION TO ADD BEVACIZUMAB) IN PATIENTS WITH REFRACTORY GESTATIONAL TROPHOBLASTIC NEOPLASIA (GTN)

• IRAS ID

  209437

• Contact name

  Michael Seckl

• Contact email

  m.seckl@imperial.ac.uk

• Sponsor organisation

  TRACON Pharmaceuticals, Inc.

• Eudract number

  2015-005475-25

• Clinicaltrials.gov Identifier

  NCT02664961

• Duration of Study in the UK

  2 years, 3 months, 1 days

• Research summary

  The study will test the use of an investigational cancer drug, TRC105, as compared to a marketed drug, bevacizumab, alone and in combination in patients with Gestational Trophoblastic Neoplasia (GTN) who have not been fully helped after chemotherapy that included two or more chemotherapy drugs.

• REC name

  South Central - Berkshire B Research Ethics Committee

• REC reference

  16/SC/0422

• Date of REC Opinion

  20 Oct 2016

• REC opinion

  Further Information Favourable Opinion